Cybin (CYBN.NE) has selected social anxiety disorder (SAD) and generalized anxiety disorder (GAD) as the targets for their CYB004 proprietary psychedelic molecule. Read full article here: https://equity.guru/2021/06/16/cybin-cybn-ne-selects-sad-and-gad-as-targets-for-their-cyb004-psychedelic-molecule/
Latest News
Digital Twinning, and how EdgeTI (CTRL.V) is a serious story you’ve never heard of
Bionxt Solutions (BNXT.C): Seeking to confirm national-level cancer drug patent
Why Prospera Energy (PEI.V) might be a transformational investment opportunity in Canadian oil & gas
Sparc AI (SPAI.C) completes development of drone advanced target acquisition system
Plurilock (PLUR.V) lands $19 million deal, largest in their history
Rex Resources (OWN.V) continues gearing up with BC gold property
